Capsugel

Lonza Divests Capsules & Health Ingredients Business for $3 Billion

Lonza signs agreement to divest its Capsules & Health Ingredients (CHI) business to Lone Star Funds, for an enterprise value of $3 billion (CHF 2.3 billion).

Topics • Technology

Mitsubishi Chem to Buy Capsule Maker from Carlyle

Top-Feature

BIO Deutschland e.V.

German Biotech Days 2026: Biotechnology as The Key to Industrial Competitiveness

Agilent Technologies Inc.

Comprehensive Insights into Antibody–Drug Conjugates (ADC) for Precision Cancer Therapy

Aenova Holding GmbH

Small Molecules: Choosing a Strategic, Scalable, and De-Risked Development Path

CHEManager c/o Wiley-VCH Verlag

Special Issue

Explore the Future of Plastics

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Lonza AG

Capsugel

Lonza Divests Capsules & Health Ingredients Business for $3 Billion

A Wide Spectrum of Contract Services

Along the Acquisition Trail

Lonza Adds More Building Blocks for the Healthcare Continuum

Lonza Completes Capsugel Acquisition

Lonza Captures Capsugel for $5.5 Billion

Lonza Confirms Talks With Capsugel

Mitsubishi Chem to Buy Capsule Maker from Carlyle

Top-Feature

German Biotech Days 2026: Biotechnology as The Key to Industrial Competitiveness

Comprehensive Insights into Antibody–Drug Conjugates (ADC) for Precision Cancer Therapy

Small Molecules: Choosing a Strategic, Scalable, and De-Risked Development Path

Upcoming Virtual Events

Special Issue

Circular Plastics Economy

Capsugel

Top-Feature

German Biotech Days 2026: Biotechnology as The Key to Industrial Competitiveness

Comprehensive Insights into Antibody–Drug Conjugates (ADC) for Precision Cancer Therapy

Small Molecules: Choosing a Strategic, Scalable, and De-Risked Development Path

Upcoming Virtual Events

Special Issue

Newsletter & e-edition